EISAI CO LTD (EII MU) stock market data APIs
€26.5665
0(0%)
as of March 27, 2026
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.MU.
Prev. Close
26.5665
Open
26.5665
High
26.5665
Low
26.5665
52 wk Range
21.5917-31.4821
Market Cap
15 022 M
EPS
39.18
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 32.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock
Nuvation Bio Inc. (NYSE:NUVB) is one of the 12 Best Stocks to Buy According to Billionaire David Abrams. Nuvation Bio Inc. (NYSE:NUVB) has been featured in the 13F portfolio of Abrams Capital Managem...
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and o...
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B ) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and r...
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Biogen Inc. Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Har...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
